BRII-297 is under clinical development by Brii Biosciences and currently in Phase I for Post Partum Depression (Maternal Depression / Postnatal Depression). According to GlobalData, Phase I drugs for Post Partum Depression (Maternal Depression / Postnatal Depression) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BRII-297’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BRII-297 overview

BRII-297 is under development for the treatment of major depressive disorder, anxiety disorders and postpartum depression. It is administered through parenteral  and intramuscular route. The drug candidate is a new chemical entity and acts by targeting GABA( A) receptors. 

Brii Biosciences overview

Brii Biosciences is a biotechnology company that develops and commercializes medicines to treat central nervous systems and infectious disease. It is investigating BRII-835 (VIR-2218) and BRII-179 (VBI-2601) against Hepatitis B virus; BRII-658 targeting multidrug-resistant TB (MDR-TB) mycobacteria; and BRII-636 (QPX-7728), BRII-672 (QPX-7831) and BRII-693 (QPX-9003) to treat infections caused due to multidrug-resistant gram-negative bacteria (MDR-GNB). The company is also evaluating BRII-732 and BRII-778 against human immunodeficiency virus (HIV); BRII-196 and BRII-198 targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); BRII-296 for paranoid personality disorder and major depressive disorder (MDD). The company has operations in China and the US. Brii Biosciences is headquartered in Shanghai, China.

For a complete picture of BRII-297’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.